These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 20069466)

  • 1. No inhibitory effect on P-glycoprotein function at blood-brain barrier by clinical dose of clarithromycin: a human PET study with [¹¹C]verapamil.
    Arakawa R; Ito H; Okumura M; Morimoto T; Seki C; Takahashi H; Takano A; Suhara T
    Ann Nucl Med; 2010 Feb; 24(2):83-7. PubMed ID: 20069466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.
    Hsiao P; Bui T; Ho RJ; Unadkat JD
    Drug Metab Dispos; 2008 Mar; 36(3):481-4. PubMed ID: 18057117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier.
    Hendrikse NH; de Vries EG; Eriks-Fluks L; van der Graaf WT; Hospers GA; Willemsen AT; Vaalburg W; Franssen EJ
    Cancer Res; 1999 May; 59(10):2411-6. PubMed ID: 10344751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography.
    Hendrikse NH; Schinkel AH; de Vries EG; Fluks E; Van der Graaf WT; Willemsen AT; Vaalburg W; Franssen EJ
    Br J Pharmacol; 1998 Aug; 124(7):1413-8. PubMed ID: 9723952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and preclinical evaluation of [11C]D617, a metabolite of (R)-[11C]verapamil.
    Verbeek J; Syvänen S; Schuit RC; Eriksson J; de Lange EC; Windhorst AD; Luurtsema G; Lammertsma AA
    Nucl Med Biol; 2012 May; 39(4):530-9. PubMed ID: 22226023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data.
    Hsiao P; Sasongko L; Link JM; Mankoff DA; Muzi M; Collier AC; Unadkat JD
    J Pharmacol Exp Ther; 2006 May; 317(2):704-10. PubMed ID: 16415090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood-brain barrier.
    de Klerk OL; Willemsen AT; Roosink M; Bartels AL; Hendrikse NH; Bosker FJ; den Boer JA
    Int J Neuropsychopharmacol; 2009 Aug; 12(7):895-904. PubMed ID: 19224656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin.
    Zong J; Pollack GM
    J Pharmacol Exp Ther; 2003 Aug; 306(2):556-62. PubMed ID: 12721332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET.
    Elsinga PH; Franssen EJ; Hendrikse NH; Fluks L; Weemaes AM; van der Graaf WT; de Vries EG; Visser GM; Vaalburg W
    J Nucl Med; 1996 Sep; 37(9):1571-5. PubMed ID: 8790221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of [11C]XR9576 to assess the function of drug efflux transporters using PET.
    Kawamura K; Konno F; Yui J; Yamasaki T; Hatori A; Yanamoto K; Wakizaka H; Takei M; Nengaki N; Fukumura T; Zhang MR
    Ann Nucl Med; 2010 Jun; 24(5):403-12. PubMed ID: 20361276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography.
    Toornvliet R; van Berckel BN; Luurtsema G; Lubberink M; Geldof AA; Bosch TM; Oerlemans R; Lammertsma AA; Franssen EJ
    Clin Pharmacol Ther; 2006 Jun; 79(6):540-8. PubMed ID: 16765142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P-glycoprotein function.
    de Klerk OL; Willemsen AT; Bosker FJ; Bartels AL; Hendrikse NH; den Boer JA; Dierckx RA
    Psychiatry Res; 2010 Aug; 183(2):151-6. PubMed ID: 20620031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil.
    Lee YJ; Maeda J; Kusuhara H; Okauchi T; Inaji M; Nagai Y; Obayashi S; Nakao R; Suzuki K; Sugiyama Y; Suhara T
    J Pharmacol Exp Ther; 2006 Feb; 316(2):647-53. PubMed ID: 16293715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography.
    Sasongko L; Link JM; Muzi M; Mankoff DA; Yang X; Collier AC; Shoner SC; Unadkat JD
    Clin Pharmacol Ther; 2005 Jun; 77(6):503-14. PubMed ID: 15961982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport.
    Syvänen S; Lindhe O; Palner M; Kornum BR; Rahman O; Långström B; Knudsen GM; Hammarlund-Udenaes M
    Drug Metab Dispos; 2009 Mar; 37(3):635-43. PubMed ID: 19047468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically.
    Ishiwata K; Kawamura K; Yanai K; Hendrikse NH
    J Nucl Med; 2007 Jan; 48(1):81-7. PubMed ID: 17204702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat.
    Luurtsema G; Molthoff CF; Schuit RC; Windhorst AD; Lammertsma AA; Franssen EJ
    Nucl Med Biol; 2005 Jan; 32(1):87-93. PubMed ID: 15691665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developmental changes in P-glycoprotein function in the blood-brain barrier of nonhuman primates: PET study with R-11C-verapamil and 11C-oseltamivir.
    Takashima T; Yokoyama C; Mizuma H; Yamanaka H; Wada Y; Onoe K; Nagata H; Tazawa S; Doi H; Takahashi K; Morita M; Kanai M; Shibasaki M; Kusuhara H; Sugiyama Y; Onoe H; Watanabe Y
    J Nucl Med; 2011 Jun; 52(6):950-7. PubMed ID: 21571790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET.
    Syvänen S; Blomquist G; Sprycha M; Höglund AU; Roman M; Eriksson O; Hammarlund-Udenaes M; Långström B; Bergström M
    Neuroimage; 2006 Sep; 32(3):1134-41. PubMed ID: 16857389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET.
    Wagner CC; Bauer M; Karch R; Feurstein T; Kopp S; Chiba P; Kletter K; Löscher W; Müller M; Zeitlinger M; Langer O
    J Nucl Med; 2009 Dec; 50(12):1954-61. PubMed ID: 19910428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.